Decision aid for patients with medullary thyroid cancer and their caregivers
Official title: Designing a Decision Aid to Help People With Medullary Thyroid Cancer Make Decisions With Their Doctors About Whether to Start or Stop New Drugs, Enroll in Clinical Trials, or Continue With Active Surveillance
Run by M.D. Anderson Cancer Center · NCT03892993 · Data updated 2026-11-12
This study is testing a new tool to help patients with medullary thyroid cancer and their caregivers make better choices about treatment and care options.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | April 9, 2019 |
| Main results expected | August 1, 2028 |
| Study ends | August 1, 2028 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT03892993 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with medullary thyroid carcinoma and their caregivers.
✕Probably not a fit
Patients with cognitive or psychological impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial focuses on developing and evaluating a patient decision aid designed to assist individuals with medullary thyroid cancer and their caregivers in making informed decisions regarding treatment options, clinical trial participation, and active surveillance. The study aims to assess the decision-making needs of patients, caregivers, and healthcare providers, and to create a prototype of the decision aid. Participants will use the decision aid and provide feedback through questionnaires to evaluate its acceptability and usability in real-world settings.
Why it matters
Potential benefit: If successful, this decision aid could empower patients and caregivers to make better-informed choices about cancer care.
How similar studies have gone: Other studies have shown success in using decision aids for cancer treatment decisions, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years old or older * Have or will face(d) this decision, including: Patient/survivor - who has medullary thyroid carcinoma, as determined by a clinician or documented in the Genetics of Endocrine Neoplasia Registry or sporadic (medullary thyroid carcinoma) MTC database; Caregiver/family member - of patient/survivor who has medullary thyroid carcinoma, as nominated by the patient/survivor; and Provider - who treats patients/survivors who have medullary thyroid carcinoma, as described above * Able to speak, read, and write English * Pregnant patients are included Exclusion Criteria: --Individuals with cognitive or psychological impairment (e.g., depression, anxiety, severe mental illness; as documented in the registry)
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Elizabeth G Grubbs, MD — M.D. Anderson Cancer Center
- Study coordinator: Elizabeth G Grubbs, MD
- Email: eggrubbs@mdanderson.org
- Phone: (713) 792-0665
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding the progression of advanced medullary thyroid cancer
This study is trying to learn more about how advanced medullary thyroid cancer develops and affects patients' lives by collecting health information and feedback from those living with the disease.
-
68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R
This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.
-
Precision surgery guided by 68Ga-CTR-FAPI for newly diagnosed medullary thyroid cancer
This trial will test whether using 68Ga-CTR-FAPI PET-CT to guide the extent of surgery improves biochemical cure rates for people with newly diagnosed medullary thyroid carcinoma.
-
68Ga-DOTA-CCK-FS PET/CT imaging for medullary thyroid cancer
This trial will test whether a new PET tracer, 68Ga-DOTA-CCK-FS, can better find medullary thyroid cancer and other CCK-2R–positive tumors than standard PET scans.
-
Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors
This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.
-
Identifying and differentiating thyroid nodules using acoustic imaging
This study is testing new imaging techniques to see if they can better identify and tell apart thyroid nodules, helping patients understand if their nodules are cancerous or not.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.